Clear Harbor Asset Management LLC Has $4.30 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Clear Harbor Asset Management LLC boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 0.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 26,404 shares of the company’s stock after purchasing an additional 75 shares during the period. Clear Harbor Asset Management LLC’s holdings in Zoetis were worth $4,302,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of ZTS. AE Wealth Management LLC lifted its position in Zoetis by 9.5% during the 2nd quarter. AE Wealth Management LLC now owns 1,988 shares of the company’s stock worth $345,000 after buying an additional 172 shares in the last quarter. Pacer Advisors Inc. raised its stake in shares of Zoetis by 32.4% in the second quarter. Pacer Advisors Inc. now owns 40,374 shares of the company’s stock worth $6,999,000 after acquiring an additional 9,872 shares during the last quarter. ProShare Advisors LLC grew its stake in shares of Zoetis by 2.5% during the second quarter. ProShare Advisors LLC now owns 109,521 shares of the company’s stock valued at $18,987,000 after purchasing an additional 2,633 shares during the last quarter. Frank Rimerman Advisors LLC increased its holdings in shares of Zoetis by 46,636.8% in the second quarter. Frank Rimerman Advisors LLC now owns 8,880 shares of the company’s stock valued at $1,539,000 after purchasing an additional 8,861 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC raised its position in Zoetis by 12.7% in the 2nd quarter. Mount Yale Investment Advisors LLC now owns 4,366 shares of the company’s stock worth $757,000 after purchasing an additional 493 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $166.01 on Tuesday. The business’s 50 day simple moving average is $170.93 and its 200 day simple moving average is $180.01. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53. The stock has a market capitalization of $74.90 billion, a PE ratio of 31.20, a PEG ratio of 2.55 and a beta of 0.89. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter last year, the firm earned $1.36 EPS. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. As a group, research analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be given a $0.50 dividend. The ex-dividend date of this dividend is Tuesday, January 21st. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a yield of 1.20%. Zoetis’s payout ratio is 32.52%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ZTS. Stifel Nicolaus lowered their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. UBS Group assumed coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price for the company. JPMorgan Chase & Co. raised their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Leerink Partners assumed coverage on Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective for the company. Finally, Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. One research analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $211.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.